1. van Zuylen, L, Verweij, J, Sparreboom, A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs. 2001;19(2):125-141. doi:10.1023/a:1010618632738.
Google Scholar | Crossref | Medline2. ten Tije, AJ, Verweij, J, Loos, WJ, Sparreboom, A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42(7):665-685. doi:10.2165/00003088-200342070-00005.
Google Scholar | Crossref | Medline | ISI3. Dranitsaris, G, Coleman, R, Gradishar, W. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Res Treat. 2010;119(3):717-724. doi:10.1007/s10549-009-0424-z.
Google Scholar | Crossref | Medline4. Picard, M. Management of hypersensitivity reactions to taxanes. Immunol Allergy Clin North Am. 2017;37(4):679-693. doi:10.1016/j.iac.2017.07.004.
Google Scholar | Crossref | Medline5. Picard, M, Castells, MC. Re-visiting hypersensitivity reactions to taxanes: a comprehensive review. Clin Rev Allergy Immunol. 2015;49(2):177-191. doi:10.1007/s12016-014-8416-0.
Google Scholar | Crossref | Medline6. Gradishar, WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7(8):1041-1053. doi:10.1517/14656566.7.8.1041.
Google Scholar | Crossref | Medline | ISI7. Gradishar, WJ, Tjulandin, S, Davidson, N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794-7803. doi:10.1200/jco.2005.04.937.
Google Scholar | Crossref | Medline | ISI8. Henderson, IC, Bhatia, V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther. 2007;7(7):919-943. doi:10.1586/14737140.7.7.919.
Google Scholar | Crossref | Medline9. Desai, N, Trieu, V, Yao, Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12(4):1317-1324. doi:10.1158/1078-0432.Ccr-05-1634.
Google Scholar | Crossref | Medline | ISI10. Yamamoto, Y, Kawano, I, Iwase, H. Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther. 2011;4:123-136. doi:10.2147/OTT.S13836.
Google Scholar | Crossref | Medline11. Liu, Y, Ye, G, Yan, D, Zhang, L, Fan, F, Feng, J. Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials. Oncotarget. 2017;22;8(42):72950-72958. doi:10.18632/oncotarget.18900.
Google Scholar | Crossref12. Emens, LA, Middleton, G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436-443. doi:10.1158/2326-6066.CIR-15-0064.
Google Scholar | Crossref | Medline13. West, H, McCleod, M, Hussein, M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924-937. doi:10.1016/S1470-2045(19)30167-6.
Google Scholar | Crossref | Medline14. Liu, SV, Camidge, DR, Gettinger, SN, et al. Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): update from a phase Ib study. Journal of Clinical Oncology. 2017;35(15 suppl):9092-9092. doi:10.1200/JCO.2017.35.15_suppl.9092.
Google Scholar | Crossref15. Jotte, RM, Cappuzzo, F, Vynnychenko, I, et al. IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. Journal of Clinical Oncology. 2018;36(18_suppl):lba9000. doi:10.1200/JCO.2018.36.18_suppl.LBA9000.
Google Scholar | Crossref16. Adams, S, Diamond, JR, Hamilton, E, et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial. JAMA Oncol. 2019;5(3):334-342. doi:10.1001/jamaoncol.2018.5152.
Google Scholar | Crossref | Medline17. Schmid, P, Adams, S, Rugo, HS, et al. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108-2121. doi:10.1056/NEJMoa1809615.
Google Scholar | Crossref | Medline18. Schmid, P, Rugo, HS, Adams, S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44-59. doi:10.1016/S1470-2045(19)30689-8.
Google Scholar | Crossref | Medline19. Moher, D, Cook, DJ, Eastwood, S, Olkin, I, Rennie, D, Stroup, DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet. 1999;354(9193):1896-1900. doi:10.1016/s0140-6736(99)04149-5.
Google Scholar | Crossref | Medline | ISI20. Gradishar, WJ, Krasnojon, D, Cheporov, S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009;27(22):3611-3619. doi:10.1200/jco.2008.18.5397.
Google Scholar | Crossref | Medline | ISI21. Guan, ZZ, Li, L, Feng, F, et al. Superior efficacy of a Cremophor-free albumin-bound paclitaxel compared with solvent-based paclitaxel in Chinese patients with metastatic breast cancer. Asia Pac J Clin Oncol. 2009;5(3):165-174. doi:10.1111/j.1743-7563.2009.01235.x.
Google Scholar | Crossref22. Rugo, HS, Barry, WT, Moreno-Aspitia, A, et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol. 2015;33(21):2361-2369. doi:10.1200/jco.2014.59.5298.
Google Scholar | Crossref | Medline23. Tamura, K, Inoue, K, Masuda, N, et al. Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. Cancer Sci. 2017;108(5):987-994. doi:10.1111/cas.13221.
Google Scholar | Crossref | Medline24. Furlanetto, J, Jackisch, C, Untch, M, et al. Efficacy and safety of nab-paclitaxel 125 mg/m(2) and nab-paclitaxel 150 mg/m(2) compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69). Breast Cancer Res Treat. 2017;163(3):495-506. doi:10.1007/s10549-017-4200-1.
Google Scholar | Crossref | Medline25. Gianni, L, Mansutti, M, Anton, A, et al. Comparing Neoadjuvant Nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/HER2-negative breast cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) trial: a randomized phase 3 clinical trial. JAMA Oncol. 2018;4(3):302-308. doi:10.1001/jamaoncol.2017.4612.
Google Scholar | Crossref | Medline26. Kuwayama, T, Nakamura, S, Hayashi, N, et al. Randomized multicenter phase ii trial of neoadjuvant therapy comparing weekly nab-paclitaxel followed by FEC with docetaxel followed by FEC in HER2(-) early-stage breast cancer. Clin Breast Cancer. 2018;18(6):474-480. doi:10.1016/j.clbc.2018.06.012.
Google Scholar | Crossref | Medline27. Ciruelos, E, Apellániz-Ruiz, M, Cantos, B, et al. A pilot, phase ii, randomized, open-label clinical trial comparing the neurotoxicity of three dose regimens of nab-paclitaxel to that of solvent-based paclitaxel as the first-line treatment for patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer. Oncologist. 2019;24(11):e1024-e1033. doi:10.1634/theoncologist.2017-0664.
Google Scholar | Crossref | Medline28. Socinski, MA, Bondarenko, I, Karaseva, NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012;30(17):2055-2062. doi:10.1200/jco.2011.39.5848
Google Scholar | Crossref | Medline | ISI29. Yoneshima, Y, Morita, S, Ando, M, et al. Treatment rationale and design for J-AXEL: a randomized phase 3 study comparing nab-paclitaxel with docetaxel in patients with previously treated advanced non-small-cell lung cancer. Clin Lung Cancer. 2017;18(1):100-103. doi:10.1016/j.cllc.2016.08.003.
Google Scholar | Crossref | Medline30. Sridhar, SS, Blais, N, Tran, B, et al. Efficacy and safety of nab-paclitaxel vs paclitaxel on survival in patients with platinum-refractory metastatic urothelial cancer: the Canadian cancer trials group BL.12 randomized clinical trial. JAMA Oncol. 2020;6(11):1-8. doi:10.1001/jamaoncol.2020.3927.
Google Scholar | Crossref31. Shitara, K, Takashima, A, Fujitani, K, et al. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2(4):277-287. doi:10.1016/S2468-1253(16)30219-9.
Google Scholar | Crossref | Medline32. Postow, MA, Sidlow, R, Hellmann, MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158-168. doi:10.1056/NEJMra1703481.
Google Scholar | Crossref | Medline33. Ramos-Casals, M, Brahmer, JR, Callahan, MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38. doi:10.1038/s41572-020-0160-6.
Google Scholar | Crossref | Medline34. Geisler, AN, Phillips, GS, Barrios, DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255-1268. doi:10.1016/j.jaad.2020.03.132.
Google Scholar | Crossref | Medline35. Habre, M, Habre, SB, Kourie, HR. Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know. Immunotherapy. 2016;8(12):1437-1446. doi:10.2217/imt-2016-0074.
Google Scholar | Crossref | Medline36. Nyman, DW, Campbell, KJ, Hersh, E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol. 2005;23(31):7785-7793. doi:10.1200/jco.2004.00.6148.
Google Scholar | Crossref | Medline | ISI37. Blum, JL, Savin, MA, Edelman, G, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer. 2007;7(11):850-856. doi:10.3816/CBC.2007.n.049.
Google Scholar | Crossref | Medline | ISI